Related Experiment Videos
[Kawasaki disease]
1Unité de réanimation pédiatrique, hôpital Edouard-Herriot, Lyon, France.
Insights
Kawasaki disease, an infectious illness primarily affecting children, presents with fever, rash, and inflammation. Early treatment with immunoglobulin and aspirin can prevent serious cardiac complications like coronary artery aneurysms.
Area of Science:
- Pediatrics
- Infectious Diseases
- Rheumatology
Context:
- Kawasaki disease, first identified in Japan in 1967, is a global health concern.
- Primarily affecting infants and young children, its exact cause remains unknown despite extensive research.
- The disease is characterized by a distinct set of clinical manifestations.
Purpose:
- To summarize the key clinical and laboratory features of Kawasaki disease.
- To highlight the significant cardiovascular risks associated with the condition.
- To outline current treatment strategies and their impact on disease progression.
Summary:
- Kawasaki disease presents with prolonged fever, conjunctivitis, oral/pharyngeal mucosal lesions, extremity changes, rash, and lymphadenopathy.
- Laboratory findings typically include an inflammatory syndrome and thrombocytosis.
- While generally self-limiting, the primary concern is cardiovascular involvement, particularly coronary artery aneurysms.
Impact:
- Cardiovascular complications, such as coronary artery aneurysms, are the leading cause of mortality (1-2%).
- Prompt treatment with intravenous immunoglobulin and aspirin is crucial.
- Early intervention significantly reduces the risk of developing coronary artery aneurysms, improving patient outcomes.
Abstract:
First described in Japan in 1967, Kawasaki disease is now observed in all countries. Despite extensive research, the aetiology of this infectious disease which affects mainly infants and young children remains mysterious. The six main clinical presentations of Kawasaki disease are: prolonged fever, conjunctivitis, lesions of the oral and pharyngeal mucosa, inflammatory reddening and swelling of the hands and feet, skin rash and cervical lymph node enlargement. Laboratory data show an inflammatory syndrome and thrombocytosis. The disease usually resolves within a few weeks. The major risk is cardiovascular involvement with pericarditis, myocarditis and, chiefly, coronary artery aneurysms which usually regress but are the main cause of mortality (1 to 2 p. 100 of the cases). Treatment consists of gammaglobulins and aspirin in high doses; when administered at an early stage, it prevents the formation of coronary aneurysms.